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PHARMACEUTICAL MARKET OF BOSNIA AND HERZEGOVINA
One of the most challenging issues in health systems of middle-income countries is unequal access
to medicines. When it comes to determining prices and reimbursement, different frames of price
regulation and distributionmargins, variousmethodological approaches, and tools for assessing the
eligibility of costs for the insured are used (Jakovljevic et al., 2016a). Most countries in the European
Union (EU) decided to regulate prices, at least when it comes to reimbursement lists (Rosian et al.,
1998; Freemantle et al., 2001; Mrazek, 2002; Mossialos et al., 2004, 2006; Mossialos and Oliver,
2005; Vogler et al., 2005, 2008, 2009, 2011, 2015; Vogler and Habimana, 2014; Walley et al., 2005;
Habl et al., 2006; Kazakov, 2007). Health legislation is one of the key elements in national and
international activities related to health, as it plays a major role in development of a comprehensive
support for individual and community health (Salihbasic, 2011).
The different and complex constitutional division as well as arrangement of price regulation
in the healthcare system in BH causes huge losses. Because of lack of uniform legislation in this
field and huge diversification in decision-making there is no adopted and unique methodology in
price determination thus the key role in price determination in each entity have decision-makers
involved in process.
The article’s objective is to critically assess the methodological quality of decision-making
process and Bosnian legislation for price determination as well as the reimbursement policy.
Bosnian authority strives toward for regulation of prices according to external referent prices
model, so this article also presents and outlines clear benefits that could be achieved if the method
of price determination is homogenized between each entity according to referent prices especially
in terms of price deviation outlined in this article.
Health system in Bosnia and Herzegovina (B&H) has fully divided jurisdiction between two
entities and State District (Federation of Bosnia and Herzegovina, Republic of Srpska, and the
Brcko District of B&H) further divided in entity Federation of B&H to 10 Cantons. This complex
structure follows the administrative, constitutional frame of B&H which consist of two entities,
State District and 10 Cantons in entity Federation of B&H. There is no single segment in this area,
which would be a part of the jurisdiction of BH’s state level authorities except for the BH’s Law on
Medicines and Medical Devices and the Agency for Medicines and Medical Devices1. Jurisdiction
of the Agency for Medicines and Medical Devices at the state level is reflected in conducting the
process of registration of medicines and medical devices.
In the Federation of B&H, the jurisdiction over the health sector is divided between the
federal government and the Cantons, which means that the health sector is organized at the
cantonal level and coordinated at the federal level (Salihbasic, 2011). As a part of the commitment
1Medicinal Product Act. “Official Gazette of Federation” BH No. 51/10 and 29/05.
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to honor the citizen’s rights to health care, it is essential that
all countries ensure accessibility of essential medicines, i.e.,
medicines that meet the priority needs of the population
(Hogerzeil, 2004, 2006; Hogerzeil et al., 2006). Reimbursement
list in the Federation of BH (hereinafter: the Federal
reimbursement list) contains only generic names. In addition
to this, the cantonal positive lists of medicines are coordinated
based on this list2, while the cantons are free in choosing trade
names of a drug1. When creating a positive list of medicines
in the cantons, the cantons must comply with the general and
specific criteria for inclusion of drugs on the canton’s positive
lists of medicines. This list should contain information about
a medicine as well as the mandatory acceptance of the prices
established by the Federal Ministry of Health3. Medicine prices
are established during negotiations of the Federal Ministry
of Health with drug manufacturers. The price includes a
manufacturing price of a drug, relevant customs duties, and
other related costs of imports for imported drugs and the amount
of wholesale margins (the maximum allowed margin is 8%)4.
In contrary to entity Federation of B&H, the health system in
entity Republic of Srpska (RS) is fully centralized. Compulsory
health insurance is regulated by the Health Insurance Fund of
RS as an independent organization, while the control over the
legality of the Fund is overseen by the ministry responsible for
public health (Salihbasic, 2011). A reimbursement list in the
Republic of Srpska is determined by the Health Insurance Fund.
Afterwards, the entire determined list of drugs becomes available
at the whole territory of RS5. In this entity, the Ministry of Health
and Social Welfare and the Health Insurance Fund establish the
system of pricing (Petrusic and Jakovljevic, 2015). The price of
drugs stated on the list is formed based on the wholesale prices
of medicines from the price list of the largest wholesalers, which
includes VAT (internal pricing)6.
When it comes to Brcko District of B&H (BD), basic
provisions of the entity’s legal regulations are in place (Hogerzeil,
2004). The organizational structure of the health sector in BDwas
determined through forming of the Department of Health. This
department is in charge of making a proposal of a reimbursement
list containing generic names of drugs. It was modeled after
the most favorable drug list in one of the entities, either the
Federation B&H or the RS6. Prices for the list of medicines of BD
are determined by the sum of the minimum manufacturer prices
and margins, which the Government of BD set in the amount of
20%7.
2Health Care Act. “Official Gazette of Federation” BH No. 30/97, with
amendments Nos. 7/02 and 70/08.
3The decision of Essential list of medicines. “Official Gazette of Federation BH”
No. 75/11; The decision of List of medicines, Solidarity Fund of Federation BH.
“Official Gazette of Federation BH” No. 67/11.
4The decision on the criteria for inclusion of medicinal products on the list
of medicines on prescription reimbursed from Health Insurance Fund of the
Republic of Srpska. “Official Gazette of Republic of Srpska” No. 2/10.
5Ministry of Health and Social Care, The strategy in the field of medicine by 2012,
16.
6Health Insurance Act, Brcko District BH, “Official Gazette of Brcko District” BH
No. 1/02, 7/02, 2/8, 19/7, and 34/08.
7The decision on the methodology of determining the reference price of medicine
from List of essential medicines for the needs of insured persons, the Health
THE DATA REPORT METHODS
Materials and Methods
The study features critical analysis of drug prices for period 2011–
2015, current methods of price determination, and impact on a
budget. We performed a cross-sectional study using the official
published data for the period 2011–2015.
The data from the official documents of Bosnia and
Herzegovina relating to the price of drugs on reimbursement
lists from certain regions in Bosnia and Herzegovina, spanning
the period from 2011 to 2015, was compared. Each region has
published different price list and it is available for each region,
Brcko District,6,7,8, Federation BH9, and Republic of Srpska10.
In more recent times in Bosnia and Herzegovina, there
is a legislative tendency to determine prices for medicines
according to external reference pricing takes into account
benchmark countries, namely: Serbia, Croatia, Slovenia, and
Italy and Bulgaria, as substitute countries (Jakovljevic, 2013). In
accordance with the current proposals of institutions in Bosnia
and Herzegovina, this paper presents economic effects of the
actual situation in Bosnia and Herzegovina, compared with the
prices in Serbia (the prices of drugs on List A—Group A. Drugs
that are prescribed and dispensed via a medical prescription,
and List A1—drugs which are prescribed and dispensed via
medical prescriptions, which have a therapeutic parallel with the
medicines from List A, in the period from 2011 to 2015.)11. Each
year, the exchange rate for themonth of June is used for the stated
period. The prices are calculated and presented in convertible
marks (BAM)12.
The total number of different INN’s listed on the
reimbursement lists in the Federation BH and the RS is the
same—138. This number is significantly lower in BD, where
Insurance Fund of Brcko District BH, “Official Gazette Brcko District BH,” No.
52/11.
8The decision on establishing the list of essential medicines for the needs of
insured persons the Health Insurance Fund of Brcko District, 04.04.2013; Table
with established changes in prices of medicines with the list of essential medicines
for the needs of insured persons of Health Insurance Fund of Brcko District B&H,
2014; Established prices of essential medicines for the needs of insured persons the
Health Insurance Fund of Brcko District, Health Insurance Fund, 07.05.2015.
9The decision for the list of essential drugs required to provide health care within
the standards of the mandatory health insurance in Federation BH, “Official
Gazette of Federation” BH, Nos. 75/11, 56/13, 74/14, and 94/15.
10Pricelist for List of medicine from A, A1, B list. Health Insurance Fund of
Republic of Srpska, 21.10.2008, 01.10.2013, and 15.03.2015.
11Ordinance of List of medicines prescribed and issued at the expense of
mandatory health insurance, “Official Gazette of the Republic of Serbia“ No.
28/11.; Ordinance of List of medicines prescribed and issued at the expense
of mandatory health insurance, “Official Gazette of Republic of Serbia,” dated
20.03.2012. Prices in Serbia in 2013. Available: http://media.dzindjija.rs/2013/09/
Lista-lekova-Sl-glasnik-76_13.pdf (accessed: 21.06.2013). Ordinance of List of
medicines prescribed and issued at the expense of mandatory health insurance,
“Official Gazette of Republic of Serbia,” No. 7/14. Ordinance of List of medicines
prescribed and issued at the expense of mandatory health insurance, “Official
Gazette of Republic of Serbia,” No. 7/14.
12Exchange rate, dated 01.06.2011.: https://www.unicredit.ba/ba/stanovnistvo/
tecajna_lista.html; Exchange rates, dated 01.06. 2012: https://www.unicredit.
ba/ba/stanovnistvo/tecajna_lista.html; Exchange rate, 03.06.2013: https://www.
unicredit.ba/ba/stanovnistvo/tecajna_lista.html; Exchange rate, dated 02.06.2014:
https://www.unicredit.ba/ba/stanovnistvo/tecajna_lista.html; Exchange rate,
dated 01.06.2015.: https://www.unicredit.ba/ba/stanovnistvo/tecajna_lista.html
(accessed: 06.12.2016).
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it only amounts to 75. What is interesting is that there is no
representative on the BD reimbursement list within the two ATC
groups (the D group—preparations for skin application and S
group—medicines which affect the sensory organs). Average
prices of medicines on lists of medicines in the Federation B&H,
RS, and BD, show considerable variations, both regarding the
average price, and the average price per individual ATC group.
To be specific, the average price of drugs on the reimbursement
list of the Federation B&H is 12.71 BAM. This price is much
higher in RS and BD, as it amounts to 29.44 and 17.07 BAM,
respectively. This difference is most striking when it comes to the
average price of medicines from Group L. Although, the average
price in this drug group in the Federation B&H was only 34.26
BAM, the RS reimbursement list of drugs shows that the medium
price was as high as 139.64 BAM.
Prices Inequalities and Impact on
Healthcare System
The consequences of price differences and differences in the
structure of the reimbursement lists for individual regions have
had the most impact on the treatment and quality of life of the
patients and the entire healthcare system.
The data from the Federation BH presented in Table 1, show
a decline in prices in accordance with the reference prices, but
significant deviations are still present. Reduction of referent
prices from 2011 to 2015 was clearly showed. Regardless gradual
reduction of prices of every region, some INNs, such as valproic
acid + sodium valproate, did not follow the trend of referent
price reduction. In 2015 price deviation of valproic acid +
sodium valproate in FBH was 54%, in RS was 72%, and in BD
72%.
For example, the deviation in prices for lamotrigine in 2011
was 9% from the reference price, in 2012 36%, 2013 was 17%.
2014 witnessed a deviation of 1%, which is a subtle deviation
from the reference price, however, in 2015, there was a sudden
increase in the difference in prices, which amounted to 42%.
This is rather significant given that this was the year of great
market preparations and policy changes related to the new
regulations on the method of price control, the method of
forming prices of medicines and the manner of reporting on the
prices of medicines in B&H. Also, the prices between entities are
significantly different, and the higher prices were observed in the
Republic of Srpska.
However, in RS, the deviations for the same medicine are
even greater. For example, in 2011 was 59%, in 2012, 71%,
in 2013, 40%, in 2014, 42%, and in 2015, 69%. It is worrying
that according to reports of the Agency for Medicinal Products
and Medical Devices, there was no reduction of total costs
for the aforementioned drug considering reduction of prices13
(Supplementary Table 1).
In 2013, there was a sudden drop in the price of medicines
in RS, but also a slight decline in other regions as well. That
year, there was a reduction in the costs for the drug lamotrigine,
however, what followed was a growth trend of total costs which
should be worrisome. It is tough to establish adequatemonitoring
13The report of distribution of medicines licensed for BH market for period from
2011 to 2015. The Agency for medicinal products and Medical Devices, Banja
Luka, 2012, 2013, 2014, 2015, 2016.
of reimbursement lists in BH due to lack of price control
mechanisms, control of consumption, and drug prescriptions,
as a result of decentralized regulations. It is also becoming
increasingly difficult to monitor the drug supply within a payer
rights.
The dataset has been submitted to a public repository
Figshare, and it is available on https://figshare.com/s/
07fa8d6d5a1e7a0eeaa4. Data has been uploaded as Excel
file while the Appendix with all INNs (https://figshare.com/
s/506f6aea67ab6208aaad) and the results are in PDF formats.
Readers are free to access and reuse these publicly available data
at the links provided above.
Reimbursement and Pricing Policies
These results indicate that there are a high inequality and
instability in the health sector. If we take into account the
reference prices in the Republic of Serbia, as well as the
mechanisms of rationalization of prescribing drugs, the result
could be to reduce the cost of treatment, which would
consequently lead to large savings in financial resources. These
resources could further be allocated toward the prevention and
stabilization of the health care system.
Significant expenses that occur due to the inability to control
the prices, impede the progress of the health system and the
introduction of new therapies, which are more efficient and
cost-effectiveness.
Limitations of a decentralized health care system in BH,
whether political, administrative, or fiscal, call into question
financial sustainability of the health sector in BH14.
Inefficiency of the organizational model present in BH
and limitations of institutional capacities and institutional
fragmentation of every region, present the biggest problem of
this concept of health care organization and causes an unequal
access to health care (Jakovljevic and Ogura, 2016). However, this
is not the case in developed countries with decentralized systems.
In fact, this concept proved to be very convenient because it
allowed access to medicines and other health care services to the
marginalized population and population living in geographically
remote areas (Forouzanfar et al., 2016). Lack of adequate
homogeneous legislation within BH and apparent differences in
prices, constitutional and administrative fragmentation, as well as
health sector jurisdiction fragmentation contribute to enormous
economic losses, which further weaken the overall health system
in Bosnia and Herzegovina. One of the ways to approach solving
of this problem should be centralization of the decision-making
processes related to medications, clear guidelines, and policies on
drugs as well as the laws and by-laws in BH, preferably through
a better implementation of these regulations and policies in a
decentralized system of supply, necessary complemented with in-
depth constitutional, and administrative reform. Only this way
full effect on health care system could be achieved.
Most of the EU countries have developed detailed criteria (e.g.,
cost-efficiency, relative efficiency, the need for medication), to
14Strategic Plan and the development of health in Federation of Bosnia and
Herzegovina for period 2008 till 2018, Ministry of Health Federation of Bosnia
and Herzegovina, Sarajevo 2008. Available: http://www.fmoh.gov.ba/images/
federalno_ministarstvo_zdravstva/zakoni_i_strategije/strategije_i_politike/
dokumenti/usvojeni_strateski_plan_1_.pdf
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help them decide when and how much is refundable. Health
Economics also called the ’Fourth Hurdle’ (Cohen et al., 2007;
Forouzanfar et al., 2016) is something that is increasingly being
used in the decision-making process (Drummond et al., 1997,
2010; Cohen et al., 2008). The pricing policy is most often
determined institutionally, where drug prices are determined
by legal regulations (e.g., legislation, regulations, and so forth).
One such example should be implemented in the health care
system in B&H with presented clear benefits of such system
implementation.
CONCLUSIVE REMARKS
The relationship between economic development and health
care system are interrelated and dependent on one another.
In most cases, the primary concern are financial costs of
health care services and social security schemes. However,
one major impact on all of the above are primarily the
overall costs of illness and early death for the society and
the individual. The concept of developing a health care
system has many similarities with the economic development
(Jakovljevic et al., 2016b). Both processes are the result of
activities which involve many sectors of society, as well as
the population as a whole, through individual and collective
decisions and actions. Social deprivation, along with economic
inequalities and housing conditions, results in a lower quality
of life and shorter life expectancy (Jakovljevic et al., 2015).
Medicines are a paramount segment of every health system,
not only for treating a disease but also because of a high
consumption of available resources in the health care system
toward drugs. The analysis of the current situation shows
that, most often, significant funds are spent on drugs that do
not have adequate therapeutic value, and this is in addition
to losses occurring as a result of a jurisdiction conflict and
overlaps in all regions of the country. This means that the
medicine sector, as well as the entire health care system in
Bosnia and Herzegovina is in need of re-organization. One of
the more important factors affecting the financial condition of
our overall health care system is the present deviation in pricing
and the inability to control them. Reimbursement regulations
and reference pricing are the key mechanisms employed by
government and regulatory bodies to manage pharmaceutical
costs (Seget, 2003). Following new trends and introducing new
methods of determining the efficiency of drugs in relation to
the resources expended, the health care services in B&H can
be improved to a great extent which would clearly present
biggest benefit to end users of healthcare system of Bosnia and
Herzegovina.
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